The mid-term and long-term effects of tourniquet use in total knee arthroplasty: systematic review

Rafaqat, Wardah; Kumar, Sudhesh; Ahmad, Tashfeen; Qarnain, Zul; Khan, Khalid Saeed; Lakdawala, Riaz Hussain

doi:10.1186/s40634-022-00471-1

Journal of Experimental Orthopaedics

Table 1 Characteristics of studies included in systematic review on mid-term and long-term effects of tourniquet use. (See additional characteristics in Additional file 1: Appendix 2)

From: The mid-term and long-term effects of tourniquet use in total knee arthroplasty: systematic review

Study Details	Study type^a	Study Proc^b	Disease^c	Allocation of Intervention^d			Tourniquet Details^e			Sample Size^f			Follow-up time (month)
Study Details	Study type^a	Study Proc^b	Disease^c	Group A	Group B	Group C	TQ press. (mm Hg) A/B/C	TQ time (min) A/B/C	TQ Type	Group A; loss to FU	Group B; loss to FU	Group C; loss to FU	Follow-up time (month)
Ajnin, et al (2014) [4]	PCS	B/L TKA	OA/RA	TQ	NT		300	NI	NI	29; 0	29; 0		8
Ejaz, et al (2014) [12]	RCT	TKA	OA	TQ	NT		250	NI	NI	33; 0	31; 0		12
Hasanain, et al (2018) [15]	RCT	B/L TKA	OA/RA	LD	SD		100–150 abv. Sys. BP/	NI	Aut.	54; NI	54; NI		3
Huang, et al (2017) [19]	RCT	TKA	OA	TQ	TXA	TQ & TXA	100 abv. Sys. BP	NI	NI	50; 0	50; 0	50; 0	6
Jawhar, et al (2019) [20]	RCT	TKA	OA	TQ	NT		360	NI	Pneum	50; 8	49; 6		6
Liu, et al (2014) [28]	RCT	TKA	OA	TQ	NT		300	83/0	Pneum	10; 0	10; 0		12
Mittal, et al (2012) [32]	RCT	U/L TKA	OA	LD	SD		300	76.54 ± 15.1/ 22.5 ± 14.4	NI	34; 2	31; 5		12
Touzopoulos, et al (2019) [48]	PCS	TKA	OA	TQ	NT		350	NI	Pneum	50; 0	50; 0		36
Zhou et al (2017) [55]	RCT	U/L TKA	OA/RA	TQ	NT		NI	NI	NI	74; 6	74; 2		6
Alexandersson et al (2018) [6]	RCT	TKA	OA	TQ	NT		300	99 ± 15/ 0	Pneum	38; 1	43; 3		3
Molt, et al (2014) [35]	RCT	TKA	OA	TQ	NT		300	NI	NI	30; 8	30; 4		24
Dennis, et al (2015) [10]	RCT	B/L TKA	OA	TQ	NT		250	42/0	Pneum	14; 1	14; 1		3
Ejaz, et al (2015) [11]	RCT	TKA	OA	TQ	NT		250	NI	NI	33; 4	31; 3		24
Rathod, et al (2014) [40]	PCS	TKA	OA	LD	SD.		250–300	71.7 ± 8.9/ 36.8 ± 13.8	Padded	40; 3	40; 4		12
Ayik, et al (2020) [7]	RCT	U/L TKA	OA	TQ	NT		100 abv. Sys. BP	NI	Pneum	35; 3	35; 2		3
Chaudhry, et al (2020) [9]	RCT	TKA	OA	TQ	NT		250–300	NI	NI	148; 31	149; 26		6
Hedge, et al (2021) [17]	PCS	U/L TKA	OA	TQ	NT		250	30	Pneum	61; 0	61; 0		60
Pinsornsak, et al (2021) [38]	RCT	TKA	OA	TQ	TQ	TQ	75/100/150 abv. Sys. BP	65.1 ± 17.3/62.1 ± 18.8/ 59.3 ± 14.9	NI	50; 2	50; 2	50; 2	3
YiZ, et al (2021) [51]	RCT	TKA	OA	LD	SD	NT	100 abv. Sys. BP	61 ± 6.55/ 10.20 ± 1.92/0	NI	50; 0	50; 0	50; 0	3
Zhao, et al (2020) [54]	RCT	U/L TKA	OA	LD	SD	NT	100 abv. Sys. BP	72.70 ± 10.84/ 19.50 ± 4.43/ 0	NI	60; 0	60; 0	60; 0	3

^aPCS Prospective Cohort Study, RCT Randomized Controlled Trial
^bProc. Procedure, B/L Bilateral, TKA Total Knee Arthroplasty, U/L Unilateral, B/L Bilateral
^cOA Osteoarthritis, RA Rheumatoid Arthritis
^dTQ Tourniquet, NT No Tourniquet, LD Long Duration, SD Short Duration, TXA Tranexamic Acid, & and
^eAbv Above, Sys Systolic, BP Blood Pressure, NI No Information, Press Pressure, min minute, Aut. Automatic, Pneum. Pneumatic
^fFU Follow-up

Back to article page